Tony Berberabe, MPH

Articles

Study Says Urologists in Solo Practice May Overuse Gonadotropin Agonists

August 5th 2015

Urologists who are in solo practice or not affiliated with a medical school may overuse primary gonadotropin-releasing hormone for men with localized prostate cancer.

Men With Intermediate or High-Risk Prostate Cancer See Survival Benefit From Increased Radiation Therapy

August 4th 2015

Men with intermediate- or high-risk prostate cancer experienced higher survival rates when given increased radiation doses than men with low-risk disease.

Concurrent Statin Use in ADT Patients Reduced All Cause, Prostate Cancer-Specific Deaths

July 29th 2015

Patients who were taking statins while also undergoing androgen deprivation therapy may experience a reduction in all-cause and prostate cancer-specific deaths.

Improved Survival Data Seen With Abiraterone as COUGAR Trial Concludes

July 27th 2015

Charles J. Ryan, MD, discusses the final survival data for pre-chemotherapy use of abiraterone from the COUGAR-AA-302 study, which demonstrated a median of 35 months for men with castration resistant prostate cancer.

Specialty Pharmacy Makes Inroads in Urology Practice

June 10th 2015

There are many processes for a urology practice to consider when partnering with a specialty pharmacy, including time and capital investments.

Amnion/Chorion Wrap Improves Outcomes Following Robot-Assisted Prostatectomy

June 7th 2015

Using an allograft made up of dehydrated human amnion/chorion membrane wrapped around the neurovascular bundle (NVB) during nerve-sparing robot-assisted radical prostatectomy improved continence and potency postsurgery, according to results of a small study.

Progress in Immunotherapy Continues, But Pseudo-Progression Is a Concern

June 5th 2015

Interest is high among urologists and medical oncologists with "the explosion of checkpoint blockade inhibition studies" that initially made inroads in melanoma and non-small cell lung cancer, but is also gaining traction in bladder cancer.

Simple Urine Biomarker Test Could Identify Early-Stage Renal Cell Carcinoma

June 4th 2015

Two urine biomarkers, aquaporin 1 and perilipin 2, could be the key to the development of a simple urine test that leads to the detection of asymptomatic, early-stage kidney cancer.

First Effective Adjuvant Treatment Identified in High-Risk Prostate Cancer

May 31st 2015

Treatment with an adjuvant combination of docetaxel, androgen deprivation therapy (ADT), and radiation therapy (RT) improved 4-year overall survival rates in patients with high-risk localized prostate cancer, when compared with ADT plus RT alone.

3rd Annual Giants of Cancer Care Class Brings Together Diverse Honorees

May 29th 2015

After weeks of deliberations, the final votes have been cast and the winners of the 2015 Giants of Cancer Care® can now be revealed.

Physicians Struggle With Antiquated Reimbursement for Next-Generation Testing

May 22nd 2015

The growing use of genetic biomarker tests to screen, monitor, diagnose, and treat patients with cancer has the potential to improve outcomes and reduce costs, but payment systems for covering and reimbursing for these tests have fallen behind the times.

Combined Imaging Approach Effectively Detects Aggressive Prostate Cancer

May 18th 2015

The combination of multiparametric MRI with a fusion-guided biopsy (MRI plus ultrasound) was more effective at detecting aggressive prostate cancer compared with either procedure alone.

Sexual Function Scores Are Better After Robotic Versus Open Surgery for Prostate Cancer

May 18th 2015

Sexual function scores were better for patients who had a robotic compared with open surgery for prostate cancer; however, comparative results for urinary function were not conclusive.

'Chilling Effect' Seen After USPSTF Recommends Against Routine PSA Testing

May 17th 2015

Since the USPSTF guideline on PSA screening the overall rate of PSA testing decreased by 50% among primary care physicians at Oregon Health & Science University.

Active Surveillance Protocols Needed for Prostate Cancer

May 16th 2015

As the AS strategy gains a foothold among urologists both here in the US and around the world, a study presented at the 110th Annual Scientific Meeting of the American Urological Association suggests that among men in the US, very few are following the stringent protocol for AS that is recommended by major academic institutions.

Presence of AR-V7 in Stromal, Epithelial Tissue Suggests Role in Carcinogenesis

May 16th 2015

The role of androgen receptor variant-7 in patients with early stage prostate cancer is not well characterized but data presented at the 2015 American Urological Association (AUA) Meeting is bringing the discussion into focus.

Olaparib Nears 90% Response in Molecular Subgroup of mCRPC

April 21st 2015

Treatment with olaparib demonstrated a durable overall response rate of 87.5% in a biomarker-defined subgroup of men with pretreated sporadic metastatic castration-resistant prostate cancer in a phase II multi-step adaptive trial.

Tasquinimod Development in mCRPC Halted After Phase III Study Falls Short

April 16th 2015

Topline results announced today from the phase III Swedish trial 10TASQ10 demonstrated that tasquinimod failed to extend overall survival in men with metastatic castrate-resistant prostate cancer.

STRIVE Data Further Demonstrate PFS Benefit With Enzalutamide Over Bicalutamide

April 2nd 2015

Treatment with enzalutamide reduced the risk of progression by 76% compared with bicalutamide in men with castration-resistant prostate cancer.

Advanced Bladder Cancer Increases Suicide Risk, Study Says

March 27th 2015

Older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary system, researchers report.